Модель посттравматического стрессового расстройства, основанная на дефиците эндоканнабиноидов: потенциальное значение для терапии
Рекомендуемое оформление библиографической ссылки:
Кэмерон К., Адиле Т., Ахмед A.Г. Модель посттравматического стрессового расстройства, основанная на дефиците эндоканнабиноидов: потенциальное значение для терапии // Российский психиатрический журнал. 2021. №2. С. 54-61.
В научном обзоре с целью анализа эндоканнабиноидной системы, нейробиологического действия каннабиноидов, а также эндоканнабиноид-дефицитарной модели посттравматического стрессового расстройства (ПТСР) рассматривается доказательная база, указывающая на возможность использования каннабиноидов при лечении ПТСР. Особое внимание уделяется исследованиям по применению набилона – синтетического агониста каннабиноидных рецепторов 1 (C1) – при бессоннице и ночных кошмарах, связанных с ПТСР, включая случаи со множеством коморбидных психических расстройств, злоупотреблением психоактивных веществ и хроническими болями. Предлагаются направления будущих исследований для дальнейшего прояснения возможностей использования каннабиноидов при лечении посттравматического стрессового расстройства.
Ключевые слова посттравматическое стрессовое расстройство (ПТСР); каннабиноиды; эндоканнабиноидная система; набилон
1. Romero-Sandoval EA, Kolano AL, Alvarado-Vázquez PA. Cannabis and Cannabinoids for Chronic Pain. Curr Rheumatol Rep. 2017;19(11):67. DOI: https://doi.org/10.1007/s11926-017-0693-1 2. Grotenhermen F, Muller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int. 2012;109(29–30):495–501. DOI: https://doi.org/10.3238/arztebl.2012.0495 3. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105(1–2):1–25. DOI: https://doi.org/10.1016/j.jep.2006.02.001 4. Zhang Y, Ren R, Sanford LD, et al. The effects of prazosin on sleep disturbances in post-traumatic stress disorder: a systematic review and meta-analysis. Sleep Med. 2020;67:225–31. DOI: https://doi.org/10.1016/j.sleep.2019.06.010 5. VA/DoD Clinical PracticeGuideline for theManagement of Posttraumatic StressDisorder andAcute StressDisorder. Department of Veterans Affairs, Department of Defence, 2017, version 3.0. URL: https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf (accessed on: 10.04.2021). 6. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52(12):1048–60. DOI: https://doi.org/10.1001/archpsyc.1995.03950240066012 7. Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety Disord. 2011;25(3):456–65. DOI: https://doi.org/10.1016/j.janxdis.2010.11.01 8. Bilevicius E, Sommer JL, Asmundson GJG, El-Gabalawy R. Associations of PTSD, chronic pain, and their comorbidity on cannabis use disorder: Results from an American nationally representative study. Depress Anxiety. 2019;36(11):1036–46. DOI: https://doi.org/10.1002/da.22947 9. Meng H, Johnston B, Englesakis M, et al. Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis. Anesth Analg. 2017;125(5):1638–52. DOI: https://doi.org/10.1213/ANE.0000000000002110 10. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain: a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72(5):735–44. DOI: https://doi.org/10.1111/j.1365-2125.2011.03970.x 11. Papaseit E, Pérez-Mañá C, Pérez-Acevedo AP, et al. Cannabinoids: from pot to lab. Int J Med Sci. 2018;15(12):1286–95. DOI: https://doi.org/10.7150/ijms.27087 12. Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516–25. DOI: https://doi.org/10.1016/j.biopsych.2015.07.028 13. Svizenska I, Dubovy P, Sulcova A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures – A short review. Pharmacol Bichem Be. 2008;90(4):501–11. DOI: https://doi.org/10.1016/j.pbb.2008.05.010 14. Hill M, Campolongo P, Yehuda R, et al. Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder. Neuropsychopharmacol. 2018;43(1):80–102. DOI: https://doi.org/10.1038/npp.2017.162 15. Jiang W, Zhang Y, Xiao L, et al. Cannabinoids promote embryonic and adult hippocampal neurogenesis and produce anxiolytic and antidepressant-like effect. J Clin Invest. 2005;115(11):3104–16. DOI: https://doi.org/10.1172/JCI.7.25509 16. Bremner JD, Randall P, Scott TM, et al. MRI-based measurements of hippocampal volume in combat-related post-traumatic stress disorder. Am J Psychiatry. 1995;152(7):973–81. DOI: https://doi.org/10.1176/ajp.152.973 17. Gilbertson MW, Shenton ME, Ciszewski A, et al. Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. Nat Neurosci. 2002;5(11):1242–7. DOI: https://doi.org/10.1038/nn.9588 18. Gurvits TV, Shenton ME, Hokama H, et al. Magnetic resonance imaging study of hippocampal volume in chronic, combat-related post-traumatic stress disorder. Biol Psychiatry. 1996;40(11):1091–9. DOI: https://doi.org/10.1016/S0006-3223(96)00229-6 19. Hill MN, Bierer LM, Makotkine I, et al. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology. 2013;38(12):2952–61. DOI: https://doi.org/10.1016/j.psynuen.2013.08.004 20. Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18–41. DOI: https://doi.org/10.7812/TPP/18-041 21. Fabre LF, McLendon D. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol. 1981;21(S1):377S–82S. DOI: https://doi.org/10.1002/j.1552-4604.1981.tb02617.x 22. Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017;19(4):23. DOI: https://doi.org/10.1007/s11920-017-0775-9 23. Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol. 1981;21(S1):417S–27S. DOI: https://doi.org/10.1002/j.1552-4604.1981.tb02622.x 24. Nabilone for Chronic Pain Management: A Review of Clinical Effectiveness, Safety, and Guidelines, Rapid Response Report: Summary with Critical Appraisal, Canadian Agency for Drugs and Technologies in Health. November 2011. URL: https://www.cadth.ca/media/pdf/htis/oct-2011/RC0306-000%20Nabilone%20for%20chronic%20pain.pdf (accessed on: 10.04.2021). 25. Ware MA, St Armand E. The abuse potential of the synthetic cannabinoid nabilone. Addiction. 2010;105(3):494–503. DOI: https://doi.org/10.1002/j.1552-4604.1981.tb02622.x 26. Lile JA, Kelly TH, Hays LR. Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating delta-9-tertrahydrocannabinol. Clin Neuropharmacol. 2012;33(5):235–42. DOI: https://doi.org/10.1097/wnf.0b013e3181e77428 27. Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther. 2009;15(1):84–8. DOI: https://doi.org/10.1111/j.1755-5949.2008.00071.x 28. Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585–8. DOI: https://doi.org/10.1016/j.psyneuen.2014.11.002 29. Meakin C, Fraser G, Boivert D, Miller C. Use of a synthetic cannabinoid (nabilone) in the ongoing management of posttraumatic stress disorder nightmares in the Canadian Armed Forces. JMVFH. 2020;6(2):3–8. DOI: https://doi.org/10.3138/jmvfh-2019-0028 30. Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol. 2014;34(5):559–64. DOI: https://doi.org/10.1097/jcp.0000000000000180
DOI: http://dx.doi.org/10.47877/1560-957Х-2021-10206
Метрики статей
Metrics powered by PLOS ALM